These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 23413196)

  • 1. Next-generation integrase inhibitors : where to after raltegravir?
    Karmon SL; Markowitz M
    Drugs; 2013 Mar; 73(3):213-28. PubMed ID: 23413196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on raltegravir and the development of new integrase strand transfer inhibitors.
    Shamroe CL; Bookstaver PB; Rokas KE; Weissman SB
    South Med J; 2012 Jul; 105(7):370-8. PubMed ID: 22766666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of HIV integrase inhibitors.
    Adams JL; Greener BN; Kashuba AD
    Curr Opin HIV AIDS; 2012 Sep; 7(5):390-400. PubMed ID: 22789987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dolutegravir for the treatment of adult patients with HIV-1 infection.
    Wu G; Abraham T; Saad N
    Expert Rev Anti Infect Ther; 2014 May; 12(5):535-44. PubMed ID: 24694091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV pharmacotherapy: A review of integrase inhibitors.
    Wong E; Trustman N; Yalong A
    JAAPA; 2016 Feb; 29(2):36-40. PubMed ID: 26818644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to HIV integrase strand transfer inhibitors: in vitro findings and clinical consequences.
    Grobler JA; Hazuda DJ
    Curr Opin Virol; 2014 Oct; 8():98-103. PubMed ID: 25128610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of HIV-1 integrase inhibitors in antiretroviral naive patients.
    Lennox JL
    Curr Opin HIV AIDS; 2012 Sep; 7(5):409-14. PubMed ID: 22789985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir.
    Canducci F; Ceresola ER; Saita D; Castagna A; Gianotti N; Underwood M; Burioni R; Lazzarin A; Clementi M
    J Antimicrob Chemother; 2013 Nov; 68(11):2525-32. PubMed ID: 23798668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
    Malet I; Subra F; Charpentier C; Collin G; Descamps D; Calvez V; Marcelin AG; Delelis O
    mBio; 2017 Sep; 8(5):. PubMed ID: 28951475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How recent findings on the pharmacokinetics and pharmacodynamics of integrase inhibitors can inform clinical use.
    Elliot E; Chirwa M; Boffito M
    Curr Opin Infect Dis; 2017 Feb; 30(1):58-73. PubMed ID: 27798496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
    Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA
    J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences among HIV-1 subtypes in drug resistance against integrase inhibitors.
    Han YS; Mesplède T; Wainberg MA
    Infect Genet Evol; 2016 Dec; 46():286-291. PubMed ID: 27353185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors.
    Podany AT; Scarsi KK; Fletcher CV
    Clin Pharmacokinet; 2017 Jan; 56(1):25-40. PubMed ID: 27317415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Integrase inhibitors - new challenges for the treatment of HIV-1 infections].
    Stock I
    Med Monatsschr Pharm; 2013 Dec; 36(12):448-59; quiz 461-2. PubMed ID: 24450269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaques.
    Massud I; Martin A; Dinh C; Mitchell J; Jenkins L; Heneine W; Pau CP; García-Lerma JG
    J Antimicrob Chemother; 2015 May; 70(5):1473-81. PubMed ID: 25630643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV integrase inhibitors: a new era in the treatment of HIV.
    Blanco JL; Whitlock G; Milinkovic A; Moyle G
    Expert Opin Pharmacother; 2015 Jun; 16(9):1313-24. PubMed ID: 26001181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrase inhibitors: a novel class of antiretroviral agents.
    Schafer JJ; Squires KE
    Ann Pharmacother; 2010 Jan; 44(1):145-56. PubMed ID: 20040702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive Review on Different Analytical Techniques for HIV 1- Integrase Inhibitors: Raltegravir, Dolutegravir, Elvitegravir and Bictegravir.
    Jain P; Thota A; Saini PK; Raghuvanshi RS
    Crit Rev Anal Chem; 2024; 54(2):401-415. PubMed ID: 35617468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to HIV integrase strand transfer inhibitors in Argentina: first interim survey.
    Cecchini DM; Castillo S; Copertari G; Lacal V; Rodriguez CG; Cassetti I
    Rev Esp Quimioter; 2019 Jun; 32(3):263-267. PubMed ID: 31037930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Integrase Inhibitors in HIV-Infected Children and Adolescents.
    Dehority W; Abadi J; Wiznia A; Viani RM
    Drugs; 2015 Sep; 75(13):1483-97. PubMed ID: 26242765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.